WHO Moves Into Prequalification Of Biosimilars; Two Anticancers First In Line
Executive Summary
The World Health Organization is to pilot the prequalification of biosimilars in a bid to make expensive cancer treatments more widely available to patients. Ritixumab and trastuzumab will be first in line. The EU generics and biosimilars industry has welcomed the initiative, saying the introduction of biosimilars in the field of oncology could lead to significant changes to standards of care for patients.
You may also be interested in...
WHO Kick-Starts Pilot For Prequalification Of Biologics/Biosimilars
Manufacturers are being invited to submit expressions of interest in relation to two anticancer monoclonal antibodies on the WHO's essential list of medicines.
WHO Kick-Starts Pilot For Prequalification Of Biologics/Biosimilars
Manufacturers are being invited to submit expressions of interest in relation to two anticancer monoclonal antibodies on the WHO's essential list of medicines.
WHO Consults On Kick-Starting Pilot On Prequalification Of Biosimilars
The World Health Organization is making inroads into its plan to prequalify biosimilars, starting with a pilot project involving two anti-cancer medicines. It has developed two assessment pathways to prequalify biosimilars, depending on whether not these products are already approved by a stringent regulatory authority. During the pilot phase, the fees associated with prequalification will be waived.